GLIKNIK INC. — Department of Health and Human Services SBIR Phase II: Background Information Rituxan and Herceptin are multi-billion dollar products that are u
GLIKNIK INC. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,500,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- NAICS
- —
- Place of performance
- MD
- Period
- —
Description
Background Information Rituxan and Herceptin are multi-billion dollar products that are useful in lymphoma and breast cancer. However, significant unmet medical need persists for certain populations such as recurrent indolent NHL, HER2 IHC 2+ patients, and treatment of patients with the FcgR3a 158 F/F polymorphism. This contract proposal is designed to: a) generate a novel anti-CD20 or anti-HER2 neu compound that will advance towards clinical trial and prove to have advantages over the currently marketed antibody compound, and b) establish a new therapeutic approach to cancer.